ArticleGenetics2026
Strong GAL4 expression compromises Drosophila fat body function.
Article in Genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
5 authors.
Funding
Abstract
The ability to direct tissue-specific overexpression of transgenic proteins in genetically tractable organisms like Drosophila melanogaster has facilitated innumerable biological discoveries. However, transgenic proteins can themselves impact cellular and physiological processes in ways that are often ignored or poorly defined. Here we discovered that the yolk-GAL4 transgene, which directs strong expression of the yeast GAL4 transcription factor in the Drosophila fat body, induces significant physiological defects in adult female flies. We found that yolk-GAL4 disrupts adipose tissue integrity and reduces fat body lipid stores, egg production, and resistance to systemic bacterial infections. Knocking down GAL4 expression in yolk-GAL4 heterozygotes using RNAi fully suppressed each of these defects, thus confirming that the GAL4 transgene product induces these phenotypes. Comparing a panel of additional fat body driver lines, we found that GAL4 expression levels directly correlate with infection susceptibility, but not with fat levels or egg production. To determine whether other transgenic proteins can impair fat body function, we constructed new fly lines in which the yolk enhancer directs expression of either cytoplasmic or nuclear-localized mCherry, or an alternative transactivator, LexA. We found that only nuclear-localized mCherry and LexA increased infection susceptibility similarly to GAL4, suggesting that intranuclear transgenic proteins in general can curtail the fat body's induced immune response in a manner highly sensitive to transgene expression strength. Additionally, these new lines can be valuable tools for future studies. More broadly, our findings highlight the potential for transgenes to substantially impact organismal biology and emphasize the importance of rigorously characterizing genetic tools to optimally leverage model systems like Drosophila.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.